These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Amorphization of different furosemide polymorphic forms during ball milling: Tracking solid-to-solid phase transformations. Wang M; Gong J; Rades T; Martins ICB Int J Pharm; 2023 Dec; 648():123573. PubMed ID: 37931725 [TBL] [Abstract][Full Text] [Related]
4. Preparation of an amorphous sodium furosemide salt improves solubility and dissolution rate and leads to a faster Tmax after oral dosing to rats. Nielsen LH; Gordon S; Holm R; Selen A; Rades T; Müllertz A Eur J Pharm Biopharm; 2013 Nov; 85(3 Pt B):942-51. PubMed ID: 24075980 [TBL] [Abstract][Full Text] [Related]
6. Solid-state amorphization of rebamipide and investigation on solubility and stability of the amorphous form. Xiong X; Xu K; Li S; Tang P; Xiao Y; Li H Drug Dev Ind Pharm; 2017 Feb; 43(2):283-292. PubMed ID: 27648489 [TBL] [Abstract][Full Text] [Related]
7. The polymorph landscape of dabigatran etexilate mesylate: Taking the challenge to bring a metastable polymorph to market. Sieger P; Werthmann U; Saouane S Eur J Pharm Sci; 2023 Jul; 186():106447. PubMed ID: 37044200 [TBL] [Abstract][Full Text] [Related]
8. A comparison of spray drying and milling in the production of amorphous dispersions of sulfathiazole/polyvinylpyrrolidone and sulfadimidine/polyvinylpyrrolidone. Caron V; Tajber L; Corrigan OI; Healy AM Mol Pharm; 2011 Apr; 8(2):532-42. PubMed ID: 21323367 [TBL] [Abstract][Full Text] [Related]
9. The influence of amorphization methods on the apparent solubility and dissolution rate of tadalafil. Wlodarski K; Sawicki W; Paluch KJ; Tajber L; Grembecka M; Hawelek L; Wojnarowska Z; Grzybowska K; Talik E; Paluch M Eur J Pharm Sci; 2014 Oct; 62():132-40. PubMed ID: 24907679 [TBL] [Abstract][Full Text] [Related]
10. Transformation of an active pharmaceutical ingredient upon high-energy milling: A process-induced disorder in Biclotymol. Schammé B; Couvrat N; Malpeli P; Dudognon E; Delbreilh L; Dupray V; Dargent É; Coquerel G Int J Pharm; 2016 Feb; 499(1-2):67-73. PubMed ID: 26707413 [TBL] [Abstract][Full Text] [Related]
12. Amino acids as co-amorphous stabilizers for poorly water soluble drugs--Part 1: preparation, stability and dissolution enhancement. Löbmann K; Grohganz H; Laitinen R; Strachan C; Rades T Eur J Pharm Biopharm; 2013 Nov; 85(3 Pt B):873-81. PubMed ID: 23537574 [TBL] [Abstract][Full Text] [Related]
13. Using Milling to Explore Physical States: The Amorphous and Polymorphic Forms of Sulindac. Latreche M; Willart JF; Guerain M; Hédoux A; Danède F J Pharm Sci; 2019 Aug; 108(8):2635-2642. PubMed ID: 30905700 [TBL] [Abstract][Full Text] [Related]
14. Cryo-TEM and AFM Observation of the Time-Dependent Evolution of Amorphous Probucol Nanoparticles Formed by the Aqueous Dispersion of Ternary Solid Dispersions. Zhao Z; Katai H; Higashi K; Ueda K; Kawakami K; Moribe K Mol Pharm; 2019 May; 16(5):2184-2198. PubMed ID: 30925218 [TBL] [Abstract][Full Text] [Related]
15. Co-amorphous systems consisting of indomethacin and the chiral co-former tryptophan: Solid-state properties and molecular mobilities. Holzapfel K; Rades T; Leopold CS Int J Pharm; 2023 Apr; 636():122840. PubMed ID: 36921746 [TBL] [Abstract][Full Text] [Related]
16. A Simultaneous Differential Scanning Calorimetry-X-ray Diffraction Study of Olanzapine Crystallization from Amorphous Solid Dispersions. Askin S; Gonçalves AD; Zhao M; Williams GR; Gaisford S; Craig DQM Mol Pharm; 2020 Nov; 17(11):4364-4374. PubMed ID: 33074007 [TBL] [Abstract][Full Text] [Related]
17. (Co-)amorphization of enantiomers - Investigation of the amorphization process, the physical stability and the dissolution behavior. Holzapfel K; Liu J; Rades T; Leopold CS Int J Pharm; 2022 Mar; 616():121552. PubMed ID: 35131351 [TBL] [Abstract][Full Text] [Related]
18. Amino acids as co-amorphous excipients for tackling the poor aqueous solubility of valsartan. Huang Y; Zhang Q; Wang JR; Lin KL; Mei X Pharm Dev Technol; 2017 Feb; 22(1):69-76. PubMed ID: 27050301 [TBL] [Abstract][Full Text] [Related]
19. Effect of amorphization method on telmisartan solubility and the tableting process. Lepek P; Sawicki W; Wlodarski K; Wojnarowska Z; Paluch M; Guzik L Eur J Pharm Biopharm; 2013 Jan; 83(1):114-21. PubMed ID: 23085331 [TBL] [Abstract][Full Text] [Related]
20. Functionalised calcium carbonate as a coformer to stabilize amorphous drugs by mechanochemical activation. Liu J; Rades T; Tho I; Kissi EO Eur J Pharm Biopharm; 2020 Oct; 155():22-28. PubMed ID: 32768607 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]